<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01221987</url>
  </required_header>
  <id_info>
    <org_study_id>110430</org_study_id>
    <nct_id>NCT01221987</nct_id>
  </id_info>
  <brief_title>Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Cervical Cancer</brief_title>
  <official_title>A Cross-sectional, Hospital-based, Epidemiological Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer (ICC) and/or Cervical Intraepithelial Neoplasia (CIN) II and/or CIN III in Sri Lanka</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The current study will elucidate the human papillomavirus type distribution in a population
      of women diagnosed with cervical high grade pre-cancerous lesions and invasive cervical
      cancer in Sri Lanka.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of human papillomavirus-16, human papillomavirus-18 in invasive cervical cancer and cervix intraepithelial neoplasia- moderate or cervix intraepithelial neoplasia- severe by short PCR fragment polymerase chain reaction and line probe assay</measure>
    <time_frame>Up to 12 months from the date of study initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of other high risk types in invasive cervical cancer and cervical intraepithelial neoplasia moderate or severe by short PCR fragment polymerase chain reaction and line probe assay</measure>
    <time_frame>Up to 12 months from the date of study initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of human papillomavirus-16, human papillomavirus-18 or other high risk types in relation to covariates</measure>
    <time_frame>Up to 12 months from the date of study initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of co-infection of human papillomavirus-16 and human papillomavirus-18 in relation to other high risk types</measure>
    <time_frame>Up to 12 months from the date of study initiation</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Neoplasms, Uterine Cervix</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Females &gt; 21 years of age, diagnosed with invasive cervical cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>Females &gt; 21 years of age, diagnosed with moderate or severe cervical intraepithelial neoplasia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cervical sampling</intervention_name>
    <description>Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Questionnaire completion</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue samples of invasive cervical cancer
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Females &gt; 21 years of age, diagnosed with invasive cervical cancer or cervical
        intraepithelial neoplasia - moderate or severe
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A female &gt; 21 years of age at the time of diagnosis of invasive cervical cancer or
             cervical intraepithelial neoplasia - moderate or severe.

          -  Histologically confirmed diagnosis of cervix intraepithelial neoplasia - moderate or
             severe, invasive cervical cancer, glandular lesions and other epithelial tumours.

          -  Written informed consent obtained from the subject prior to study start.

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol, should be enrolled in the study.

        Exclusion Criteria:

          -  Previous vaccination against human papillomavirus.

          -  History of chemotherapy or radiotherapy for cervical cancer.

          -  Subjects with recurrent episodes of invasive cervical cancer or cervical
             intraepithelial neoplasia- moderate or severe.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Sri Lanka</country>
  </removed_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human papillomavirus</keyword>
  <keyword>neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

